Question · asked by 1 review
Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection: Adverse events (participants with >=1 adverse event)
- Population
- Adults with Parkinson's disease and sialorrhea (drooling)
- Intervention
- Intraglandular botulinum neurotoxin (BoNT) injection
- Comparison
- placebo injection
- Outcome
- Adverse events (participants with >=1 adverse event)
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 2 · 66.7%Very low 0 · 0%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia), BoNT type A Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup). The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | RD 0.10 [0.00, 0.21] | 5 studies · 117 participants | GRADE not reported |
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) Botulinum toxin injection increases the risk of adverse events versus placebo in Parkinson's disease sialorrhea (RD 0.15, 95% CI 0.05 to 0.24; low certainty); most events were mild and self-limited. The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | RD 0.15 [0.05, 0.24] | 10 studies · 249 participants | Low |
Botulinum toxin (BoNT) injection into salivary glands vs Placebo injection Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling) · Approximately 1 month post-injection (one study ~1 week), Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia), BoNT type B Type B botulinum toxin significantly increased adverse events versus placebo (RD 0.18, 95% CI 0.04 to 0.33; ungraded subgroup); no significant difference between types A and B (p=0.37). The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's… (2023) All outcomes | RD 0.18 [0.04, 0.33] | 5 studies · 132 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review… 2023 All outcomes | April 2022 | 8 | Critically Low / Critically Low |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.